Polyclonal Immunoglobulin PD-L1 Binding Transgenic Ungulate
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapies for cancer, such as monoclonal antibodies targeting the PD-L1/PD-1 axis, have limitations in efficacy and safety, necessitating the development of alternative immunoglobulin products that can effectively bind and inhibit PD-L1 with enhanced therapeutic benefits.
Innovation Solution
A polyclonal human immunoglobulin product derived from genetically engineered ungulates, specifically designed to bind PD-L1, is produced by immunizing transgenic animals with a PD-L1 antigenic fragment, resulting in a composition that exhibits high affinity, complement-dependent cytotoxicity, and antibody-dependent cellular toxicity, while blocking the PD-1 signaling pathway.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies are used to target PD-L1, then specific binding to PD-L1 is achieved, but therapeutic efficacy and safety are limited
Solution Approach 1:
The patent segments the antibody response into multiple clonal lines by using polyclonal immunoglobulins instead of monoclonal antibodies. This allows the therapeutic product to encompass diverse antibody specificities (including PD-L1 binding and other immune checkpoint molecules) while maintaining overall therapeutic efficacy and safety benefits
Solution Approach 2:
The patent creates a composite immunoglobulin product containing multiple antibody types (IgG, IgM, IgA, IgE, IgD) from different clonal lines. This composite approach combines the advantages of various antibody specificities and mechanisms of action to achieve superior therapeutic efficacy and safety compared to single-clonal antibodies
2Reliability
If polyclonal human immunoglobulin is produced in transgenic ungulates, then enhanced therapeutic benefits are achieved, but production complexity increases
Solution Approach 1:
The patent uses transgenic ungulates as biological copies that naturally produce human immunoglobulins. By copying the human immune system's natural antibody production mechanisms in these animals, the patent simplifies the overall production process compared to complex cell culture or recombinant DNA systems, while maintaining enhanced therapeutic benefits
Solution Approach 2:
The transgenic ungulates self-produce the human immunoglobulins through their engineered immune systems without requiring complex external intervention. The animals naturally generate the therapeutic antibodies when immunized with appropriate antigens, reducing production complexity while enhancing therapeutic efficacy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polyclonal immunoglobulin product demonstrates superior binding affinity and cytotoxic activity against PD-L1-expressing cancer cells, offering enhanced therapeutic benefits compared to monoclonal antibodies, including tumor growth inhibition and improved effector cell function.
Implementation Method 1
a population of human immunoglobulins specifically binds Programmed Death-Ligand 1 (PD-L1)
Implementation Method 2
The polyclonal immunoglobulin product demonstrates superior binding affinity and cytotoxic activity against PD-L1-expressing cancer cells
Implementation Method 3
the composition exhibits high affinity, complement-dependent cytotoxicity, and antibody-dependent cellular toxicity
Data Source
AI summary
Provided are human polyclonal immunoglobulin products specific for Programmed Death-Ligand 1 (PD-L1) for use in treating or preventing cancer. Further provided are methods for making such compositions in a transgenic ungulate, e.g. using a transchromosomic bovine (TcB) system.